160 related articles for article (PubMed ID: 8786651)
21. Why most randomized phase II cervical cancer chemoprevention trials are uninformative: lessons for the future.
Follen M; Meyskens FL; Atkinson EN; Schottenfeld D
J Natl Cancer Inst; 2001 Sep; 93(17):1293-6. PubMed ID: 11535703
[No Abstract] [Full Text] [Related]
22. Chemoprevention of cervical cancer.
Sasieni P
Best Pract Res Clin Obstet Gynaecol; 2006 Apr; 20(2):295-305. PubMed ID: 16386963
[TBL] [Abstract][Full Text] [Related]
23. Specific keynote: chemoprevention of ovarian cancer: the journey begins.
Ozols RF; Daly MB; Klein-Szanto A; Hamilton TC; Bast RC; Brewer MA
Gynecol Oncol; 2003 Jan; 88(1 Pt 2):S59-66; discussion S67-70. PubMed ID: 12586088
[No Abstract] [Full Text] [Related]
24. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
25. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
26. In silico analysis of protein neoplastic biomarkers for cervix and uterine cancer.
Rodríguez-Pérez MA; Medina-Aunon A; Encarnación-Guevara SM; Bernal-Silvia S; Barrera-Saldaña H; Albar-Ramírez JP
Clin Transl Oncol; 2008 Oct; 10(10):604-17. PubMed ID: 18940741
[TBL] [Abstract][Full Text] [Related]
27. Potential criteria for cohort selection in chemoprevention trials of epithelial ovarian cancer.
Baker VV
J Cell Biochem Suppl; 1995; 23():243-6. PubMed ID: 8747404
[TBL] [Abstract][Full Text] [Related]
28. Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR.
Das H; Koizumi T; Sugimoto T; Chakraborty S; Ichimura T; Hasegawa K; Nishimura R
Br J Cancer; 2000 May; 82(10):1682-8. PubMed ID: 10817504
[TBL] [Abstract][Full Text] [Related]
29. Intermediate biomarkers of precancer and their application in chemoprevention.
Kelloff GJ; Malone WF; Boone CW; Steele VE; Doody LA
J Cell Biochem Suppl; 1992; 16G():15-21. PubMed ID: 1469895
[TBL] [Abstract][Full Text] [Related]
30. Physical activity and gynecologic cancer prevention.
Cust AE
Recent Results Cancer Res; 2011; 186():159-85. PubMed ID: 21113764
[TBL] [Abstract][Full Text] [Related]
31. Chemoprevention of ovarian cancer.
Hoekstra A; Rodriguez GC
Cancer Treat Res; 2009; 149():3-34. PubMed ID: 19763429
[No Abstract] [Full Text] [Related]
32. Statistical validation of intermediate markers of precancer for use as endpoints in chemoprevention trials.
Freedman LS; Schatzkin A; Schiffman MH
J Cell Biochem Suppl; 1992; 16G():27-32. PubMed ID: 1469902
[TBL] [Abstract][Full Text] [Related]
33. ACOG committee opinion. Routine cancer screening. Number 247, December 2000.
ACOG committee
Int J Gynaecol Obstet; 2003 Aug; 82(2):241-5. PubMed ID: 12926412
[No Abstract] [Full Text] [Related]
34. Cancer prevention and screening in women.
Melnikow J; Nuovo J
Prim Care; 1997 Mar; 24(1):15-26. PubMed ID: 9016727
[TBL] [Abstract][Full Text] [Related]
35. BRCA1 and BRCA2 mutation carriers as potential candidates for chemoprevention trials.
Levy-Lahad E; Krieger M; Gottfeld O; Renbaum P; Klein G; Eisenberg S; Lahad A; Kaufman B; Catane R
J Cell Biochem Suppl; 2000; 34():13-8. PubMed ID: 10762009
[TBL] [Abstract][Full Text] [Related]
36. Retinoids for ovarian cancer prevention: laboratory data set the stage for thoughtful clinical trials.
Veronesi U; Decensi A
J Natl Cancer Inst; 2001 Apr; 93(7):486-8. PubMed ID: 11287432
[No Abstract] [Full Text] [Related]
37. [Mass screening of gynecological cancers in public health].
Solignac M
Presse Med; 2003 Jan; 32(2):88-91. PubMed ID: 12653035
[No Abstract] [Full Text] [Related]
38. Chemoprevention of lung cancers: lessons from CARET, the beta-carotene and retinol efficacy trial, and prospects for the future.
Omenn GS
Eur J Cancer Prev; 2007 Jun; 16(3):184-91. PubMed ID: 17415088
[TBL] [Abstract][Full Text] [Related]
39. Serum level of macrophage colony-stimulating factor as a marker for gynecologic malignancies.
Suzuki M; Ohwada M; Sato I; Nagatomo M
Oncology; 1995; 52(2):128-33. PubMed ID: 7854772
[TBL] [Abstract][Full Text] [Related]
40. [Chemoprevention of cancers].
Espie M
Bull Cancer; 1995 Jul; 82 Suppl 3():181s-185s. PubMed ID: 7492832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
